Literature DB >> 4027867

Iridium afterloading curietherapy in the treatment of pediatric malignancies. The Institut Gustave Roussy experience.

A Gerbaulet, X Panis, F Flamant, D Chassagne.   

Abstract

Between 1972 and 1980, 58 children with malignant tumors underwent iridium 192 (192Ir) curietherapy at the Institut Gustave Roussy. Data from only 45 of them were reviewed (bilateral retinoblastoma and salvage procedures were excluded). The pathologic diagnosis was rhabdomyosarcoma in 75% of cases, yolk sac tumor in 13% of cases, malignant mesenchymoma in two cases, clear cell carcinoma in two cases, and undifferentiated sarcoma in one case. The two major sites were pelvis-perineum (64.5%) and head and neck (31%). The treatment was essentially based on a combination of chemotherapy, which was adapted to the histologic type of the tumor, and curietherapy. Partial surgery was carried out in certain cases, either before chemotherapy for diagnostic purposes, or after chemotherapy to remove infiltrative residual tumor. External beam radiotherapy was used in a few cases in lymph node irradiation. The radioactive material was 192Ir, using afterloading techniques, either intracavitary or interstitially or both. The tumor dose, calculated by computerized dosimetry, was 60 to 65 Gy delivered over 5 to 7 days in the majority of cases. Two patients were lost to follow-up. Thirty-five patients (78%) are alive with no evidence of disease after a mean follow-up period of 5 years. Eight patients died, one of complications related to chemotherapy and seven of the evolution of their disease. The late-complication rate, studied in 33 patients with a minimum follow-up period of 3 years, is 18% (6/33). Curietherapy seems to be a preferable conservative treatment in children with localized and accessible malignant tumors.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4027867     DOI: 10.1002/1097-0142(19850915)56:6<1274::aid-cncr2820560609>3.0.co;2-8

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  3 in total

1.  High-dose-rate brachytherapy for soft tissue sarcoma in children: a single institution experience.

Authors:  Gustavo A Viani; Paulo E Novaes; Alexandre A Jacinto; Celia B Antonelli; Antonio Cassio A Pellizzon; Elisa Y Saito; João V Salvajoli
Journal:  Radiat Oncol       Date:  2008-04-19       Impact factor: 3.481

2.  Low dose-rate interstitial brachytherapy in soft tissue sarcomas.

Authors:  E Rosenblatt; N Meushar; M Eidelman; A Kuten
Journal:  Sarcoma       Date:  1999

Review 3.  Brachytherapy in paediatric malignancies - review of indications.

Authors:  Jacek Fijuth
Journal:  J Contemp Brachytherapy       Date:  2010-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.